[1] LUCAS M J, BROUWER M C, VAN DE BEEK D. Neurological sequelae of bacterial meningitis[J]. J Infect,2016,73(1):18-27. doi:  10.1016/j.jinf.2016.04.009
[2] 国家卫生计生委医政医管局, 国家卫生计生委合理用药专家委员会. 国家抗微生物治疗指南[M]. 2版. 北京: 人民卫生出版社, 2017.
[3]

BLASSMANN U, ROEHR A C, FREY O R, et al. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study[J]. Crit Care,2016,20(1):343. doi:  10.1186/s13054-016-1523-y
[4]

AUTMIZGUINE J, MORAN C, GONZALEZ D, et al. Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections[J]. Pediatr Infect Dis J,2014,33(10):e270-e272. doi:  10.1097/INF.0000000000000385
[5]

TUNKEL A R, HASBUN R, BHIMRAJ A, et al. 2017 infectious diseases society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis[J]. Clin Infect Dis,2017,64(6):e34-e65. doi:  10.1093/cid/ciw861
[6] 戴维·吉尔伯特. 桑福德抗微生物治疗指南[M]. 北京: 中国协和医科大学出版社, 2019.
[7] 黄亮, 罗蓉. 儿童细菌性脑膜炎抗生素的规范治疗[J]. 中华实用儿科临床杂志, 2019, 34(12):898-902.
[8] 何志超, 伍俊妍, 邱凯锋. 万古霉素个体化给药临床药师指引[J]. 今日药学, 2015, 25(2):78-82.
[9]

LE SAUX N, CANADIAN PAEDIATRIC SOCIETY, INFECTIOUS DISEASES AND IMMUNIZATION COMMITTEE. Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age[J]. Paediatr Child Health,2014,19(3):141-152. doi:  10.1093/pch/19.3.141
[10]

CHU Y, LUO Y F, QUAN X W, et al. Intermittent vs. continuous vancomycin infusion for gram-positive infections: a systematic review and meta-analysis[J]. J Infect Public Health,2020,13(4):591-597. doi:  10.1016/j.jiph.2019.09.001
[11] 刘露, 吴知桂, 范清泽, 等. 万古霉素持续输注与间歇输注有效性与安全性比较的Meta分析[J]. 中国药房, 2020, 31(22):2774-2780.
[12]

LEE C Y, HUANG C H, LU P L, et al. Role of rifampin for the treatment of bacterial infections other than mycobacteriosis[J]. J Infect,2017,75(5):395-408. doi:  10.1016/j.jinf.2017.08.013
[13] 万古霉素临床应用剂量专家组. 万古霉素临床应用剂量中国专家共识[J]. 中华传染病杂志, 2012, 30(11):641-646.
[14]

NAU R, SÖRGEL F, EIFFERT H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections[J]. Clin Microbiol Rev,2010,23(4):858-883. doi:  10.1128/CMR.00007-10
[15]

VAN DE BEEK D, CABELLOS C, DZUPOVA O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis[J]. Clin Microbiol Infect,2016,22(Suppl 3):S37-S62.
[16]

CATALDO M A, TACCONELLI E, GRILLI E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis[J]. J Antimicrob Chemother,2012,67(1):17-24. doi:  10.1093/jac/dkr442
[17]

HE N, SU S, YE Z K, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Clin Infect Dis,2020,71(Suppl_4):S363-S371.